BAO PHARMA-B(02659.HK)

Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administered ceftriaxone sodium for the treatment of bacterial infections; and KJ101, a recombinant human chymotrypsin developed through synthetic biology.